📊 ORKA Key Takeaways
Is Oruka Therapeutics, Inc. (ORKA) a Good Investment?
Oruka is a pre-revenue pharmaceutical company with zero commercial revenue despite operating losses of $36.4M annually, representing a fundamental execution risk typical of early-stage biotech. While the balance sheet is strong with $486.7M equity and minimal debt, the company is burning ~$23.6M in cash annually with only ~2 years of runway, creating substantial dilution risk as additional capital will be required. Without approved marketed products or clear pipeline visibility, the company remains entirely dependent on successful clinical trials and regulatory approval, making fundamentals unsustainable.
Pre-revenue with substantial operating losses and negative cash flow indicate no current profitability, but the balance sheet is robust with high equity, no debt, and exceptional liquidity. This provides funding capacity to continue development without leverage, yet fundamentals lack revenue visibility and efficiency proof. Risk/reward appears balanced until operating efficiency improves or revenue initiates.
Oruka Therapeutics, Inc. Key Strengths (ORKA)
- Fortress balance sheet with $486.7M stockholders' equity and minimal debt (0.00x debt-to-equity)
- Exceptional liquidity position with 23.76x current ratio and $49.5M cash balance
- Low liability burden ($17.8M) relative to asset base provides financial flexibility
- Exceptional liquidity (current/quick 22.37x)
- No debt; Debt/Equity 0.00x with minimal liabilities
- Large equity base ($471.93M) supporting ongoing R&D investment
ORKA Stock Risks: Oruka Therapeutics, Inc. Investment Risks
- Zero revenue with no commercial products generating sales, indicating pre-commercialization stage
- Significant annual cash burn of $23.6M with only ~2 year runway at current burn rate
- Negative operating cash flow and free cash flow with no clear path to profitability near-term
- Execution risk inherent to biotech: success entirely dependent on clinical trial outcomes and regulatory approvals
- Inevitable dilutive capital raises required to extend runway and fund continued R&D
- Zero revenue and structurally negative profitability (Net Income -$105.43M)
- High cash burn (OCF -$88.21M; FCF -$88.42M) implying potential future dilution needs
- Negative interest coverage (-81.4x) and EPS deterioration YoY
Key Metrics to Watch
- Clinical trial progress and regulatory approval status for pipeline candidates
- Monthly cash burn rate and updated cash runway projections
- Quarterly operating cash flow trend and when/if the company approaches profitability
- Capital raise announcements and resulting shareholder dilution impact
- Operating cash flow (burn rate)
- Cash & equivalents (liquidity runway)
Oruka Therapeutics, Inc. (ORKA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 23.76x current ratio provides a solid financial cushion.
ORKA Profit Margin, ROE & Profitability Analysis
ORKA vs Healthcare Sector: How Oruka Therapeutics, Inc. Compares
How Oruka Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oruka Therapeutics, Inc. Stock Overvalued? ORKA Valuation Analysis 2026
Based on fundamental analysis, Oruka Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oruka Therapeutics, Inc. Balance Sheet: ORKA Debt, Cash & Liquidity
ORKA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oruka Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.87 indicates the company is currently unprofitable.
ORKA Revenue Growth, EPS Growth & YoY Performance
ORKA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | N/A | -$1.1M | $-0.10 |
| Q1 2024 | N/A | -$1.1M | $-0.09 |
| Q3 2023 | N/A | -$1.2M | $-0.10 |
| Q1 2023 | N/A | -$1.2M | $-0.09 |
| Q3 2022 | N/A | -$2.3M | $-0.16 |
| Q2 2022 | N/A | -$3.1M | $-0.22 |
| Q1 2022 | N/A | -$3.3M | N/A |
| Q3 2021 | N/A | -$1.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Oruka Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ORKA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oruka Therapeutics, Inc. (CIK: 0000907654)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ORKA
What is the AI rating for ORKA?
Oruka Therapeutics, Inc. (ORKA) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ORKA's key strengths?
Claude: Fortress balance sheet with $486.7M stockholders' equity and minimal debt (0.00x debt-to-equity). Exceptional liquidity position with 23.76x current ratio and $49.5M cash balance. ChatGPT: Exceptional liquidity (current/quick 22.37x). No debt; Debt/Equity 0.00x with minimal liabilities.
What are the risks of investing in ORKA?
Claude: Zero revenue with no commercial products generating sales, indicating pre-commercialization stage. Significant annual cash burn of $23.6M with only ~2 year runway at current burn rate. ChatGPT: Zero revenue and structurally negative profitability (Net Income -$105.43M). High cash burn (OCF -$88.21M; FCF -$88.42M) implying potential future dilution needs.
What is ORKA's revenue and growth?
Oruka Therapeutics, Inc. reported revenue of $0.0.
Does ORKA pay dividends?
Oruka Therapeutics, Inc. does not currently pay dividends.
Where can I find ORKA SEC filings?
Official SEC filings for Oruka Therapeutics, Inc. (CIK: 0000907654) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ORKA's EPS?
Oruka Therapeutics, Inc. has a diluted EPS of $-0.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ORKA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Oruka Therapeutics, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ORKA stock overvalued or undervalued?
Valuation metrics for ORKA: ROE of -6.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ORKA's AI grade for 2026?
Our dual AI analysis gives Oruka Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ORKA's free cash flow?
Oruka Therapeutics, Inc.'s operating cash flow is $-23.6M, with capital expenditures of $73.0K.
How does ORKA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -6.5% (avg: 15%), current ratio 23.76 (avg: 2).